Literature DB >> 7794307

A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group.

J Ninane1.   

Abstract

A randomized, comparative study was conducted in 502 patients in 23 centres world-wide to assess the efficacy and safety of fluconazole versus nystatin and amphotericin B for prevention of fungal infection in a severely immunocompromised pediatric population. Patients scheduled within 48 hours to undergo chemotherapy or radiotherapy for hematological or oncological malignancies were randomly allocated to receive 3 mg/kg oral fluconazole once daily, 50,000 U/kg oral nystatin four times daily or 25 mg/kg oral amphotericin B four times daily. Prophylaxis began with the initiation of chemotherapy or radiotherapy and continued throughout a patient's hospital stay or period of neutropenia as necessary. The mean duration of fluconazole prophylaxis was 27.8 days and of the oral polyenes 29.2 days. The outcome of prophylaxis with fluconazole was significantly superior to that with the polyenes (p = 0.01). Mycologically verified infections occurred in 5 patients (2.1%) given fluconazole and in 21 (8.4%) given polyenes (p = 0.002). Clinical evaluation at the end of prophylaxis showed that the clinical outcome was definitely or possibly successful in 87% in the fluconazole group and 82% in the polyenes group with no significant differences between the treatment groups. Mycological evaluation demonstrated reduction or control of colonization in 84% in the fluconazole group and 85% in the polyenes group, again with no significant between-group differences. Possibly drug-related side effects, mainly mild to moderate gastrointestinal disturbances, were reported in 38 patients given fluconazole, with eight subsequent withdrawals, and in 21 patients given oral polyenes, with three subsequent withdrawals. Laboratory test abnormalities occurred in 28 patients given fluconazole and 24 given polyenes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7794307     DOI: 10.1007/bf01974614

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Prophylaxis of oropharyngeal candidiasis with fluconazole.

Authors:  G Samonis; K Rolston; C Karl; P Miller; G P Bodey
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

2.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

3.  [Infection 1979 to 1986. Epidemiology, etiology, clinical aspects and prognosis in 691 patients].

Authors:  F Müller; M Hund; J Löhr; H Lode; J Wagner; W Fangmann
Journal:  Med Klin (Munich)       Date:  1989-07-15

4.  Fungal infection and fever of unknown origin in neutropenic patients.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1986-05-30       Impact factor: 4.965

5.  Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia.

Authors:  P A Pizzo; K J Robichaud; F A Gill; F G Witebsky
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

6.  Fatal infections in childhood leukemia.

Authors:  W T Hughes
Journal:  Am J Dis Child       Date:  1971-10

7.  Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group.

Authors: 
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

8.  Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial.

Authors:  J E Karp; W G Merz; C Hendricksen; B Laughon; T Redden; B J Bamberger; J G Bartlett; R Saral; P J Burke
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

Review 9.  Symposium on infectious complications of neoplastic disease (Part II). Chemoprophylaxis of bacterial infections in granulocytopenic patients.

Authors:  S A Henry
Journal:  Am J Med       Date:  1984-04       Impact factor: 4.965

Review 10.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more
  27 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 3.  Interventions for preventing oral candidiasis for patients with cancer receiving treatment.

Authors:  J E Clarkson; H V Worthington; O B Eden
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Authors:  Oliver A Cornely; Angelika Böhme; Dieter Buchheidt; Hermann Einsele; Werner J Heinz; Meinolf Karthaus; Stefan W Krause; William Krüger; Georg Maschmeyer; Olaf Penack; Jörg Ritter; Markus Ruhnke; Michael Sandherr; Michal Sieniawski; Jörg-Janne Vehreschild; Hans-Heinrich Wolf; Andrew J Ullmann
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

Review 5.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2013-11-08

6.  Fungal chemoprophylaxis with fluconazole in preterm infants.

Authors:  José Manuel Martínez Sesmero; Francisco José Farfán Sedano; Teresa Molina García; Marta Muro Brussi; Javier Sánchez-Rubio Ferrández; Raúl Díez Fernández; Cristóbal Montojo Guillén
Journal:  Pharm World Sci       Date:  2005-12

Review 7.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2012-02-20

8.  Potential inhibition of alkylating agent metabolism by fluconazole.

Authors:  S M Yule; D Walker; A D Pearson; J R Idle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

Review 9.  Nystatin prophylaxis and treatment in severely immunodepressed patients.

Authors:  Peter C Gøtzsche; Helle Krogh Johansen
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

Review 10.  Candidiasis (oropharyngeal).

Authors:  Caroline L Pankhurst
Journal:  BMJ Clin Evid       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.